HIV

The findings suggest that the research conducted will be useful in enhancing the development of the HIV vaccine and can also be used to improve other viral pathogens.

Pharmacists play key roles in performing comprehensive patient reviews, reducing polypharmacy.

Errors risk transmission of blood-borne pathogens, including HBV, HCV, HIV, to health care providers, patients.

Social norms appear to influence individual behavior more than personal attitudes among people living with HIV.

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

CCR5 mutation creates a challenge for HIV to infect more cells, thereby creating resistance to the virus.

Bictegravir/emtricitabine/ tenofovir alafenamide tablets (B/F/TAF) provides long-term virologic suppression for nearly 100% of patients.

Structural inequalities that contribute to HIV acquisition are known to also contribute to housing stability, and this was apparent in findings regarding race and ethnicity.

A barrier in effectively treating HIV has been the latency of infected CD4+ T cells, which are often treatment-resistant and contribute to the persistence nature of the virus.

Study findings may help guide efforts to develop effective HIV vaccines and antibody-based HIV treatments.

Patients with HIV were no less likely to show a worse clinical presentation following tecovirimat treatment.

A new FDA policy would assess blood donor eligibility using a set of individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

At least 58% of mice treated with combined CRISPR therapies showed signs of complete HIV-1 viral elimination.

The analysis, published in Nature Communications, demonstrates glycan trimming also keeps the antibody response away from immunodominant glucan holes and patches.

Both barriers and facilitating factors, as well as a history of STIs, are associated with recent PrEP use among urban transgender women.

The risk is particularly high in the first 2 years after an HIV diagnosis.

Women who are pregnant should continue or start treatment with alternative or preferred antiretroviral therapies for viral suppression, investigators suggest.

Among those without HIV, the analyses found that respondents with a history of COVID-19 performed worse on processing speed than those who had never had COVID-19.

Implementing PrEP in retail community pharmacies increases patient accessibility but may be difficult to incorporate without modifying workflow.

There has been a historical lack of complete or appropriate data on sexual and gender minority groups, leading to difficulties in analyzing health outcomes in LGBTQ+ community.

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.

Removing the word ‘risk’ from discussions of HIV PrEP and focusing more on environment and empowerment concerns are beneficial in this patient population.

Any living person with HIV should be screened for hepatitis B and C upon diagnosis, with annual screenings recommended for those with additional risk factors.

Currently, APHA has a policy on its books that opposes both drug legalization and decriminalization.

Clinical decision support, packaging changes can help stop errors related to the HIV medication.